Step 1 topics → Microbiology → Mycobacterium tuberculosis

Mycobacterium tuberculosis

USMLE Step 1 trap: Confuses upper-lobe predilection of reactivation TB with the lower/middle-zone Ghon focus of primary TB. Primary TB typically causes a Ghon focus in the lower or middle lung zones (well-ventilated areas), while reactivation TB preferentially affects the upper lobes due to higher oxygen tension.

Mycobacterium tuberculosis is one of the highest-yield organisms on USMLE Step 1, spanning microbiology, pathology, pharmacology, and clinical medicine simultaneously. Drug toxicities are the most consistently mislabeled: peripheral neuropathy belongs to isoniazid (INH inhibits pyridoxine metabolism), not rifampin — rifampin's signatures are hepatotoxicity and potent CYP450 induction. Students who assign neuropathy to rifampin will miss every drug toxicity question that swaps the answer between RIPE agents. The organism is identified by acid-fast staining (Ziehl-Neelsen), with a waxy mycolic acid wall that resists gram staining. The pathology is type IV hypersensitivity — granuloma formation with caseous necrosis — and understanding why that happens is what ties primary, reactivation, and miliary TB together mechanistically.

The exam tests TB from several angles. For pathology, you need to distinguish primary from reactivation from miliary disease — not just as definitions, but by location, host immune context, and morphology. For diagnosis, you'll be asked to choose between PPD and IGRA given a specific patient profile (BCG-vaccinated? Immunocompromised?). For pharmacology, RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) is tested heavily through drug-specific toxicity questions, where individual drugs are deliberately swapped to exploit memorization errors. The extrapulmonary manifestations — Pott disease, Pott puffy tumor, lupus vulgaris, scrofula — each have named presentations you're expected to recognize in a vignette.

The trickiest part is that students collapse all TB into a single mental picture and miss the mechanistic distinctions. Primary TB isn't just 'early TB' — it has a specific anatomical signature (lower/middle zone Ghon focus) that's the opposite of reactivation TB. Drug toxicities get crossed constantly: students assign peripheral neuropathy to rifampin instead of isoniazid, and they forget that pyridoxine supplementation is prophylactic, not a rescue therapy. USMLE Step 1 exploits these exact confusions in vignette stems — know the distinctions cold.

From real student decks
84%have cards covering this topic
78%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Primary TB always affects the upper lobes of the lung.
Right: Primary TB typically causes a Ghon focus in the lower or middle lung zones (well-ventilated areas), while reactivation TB preferentially affects the upper lobes due to higher oxygen tension.
Primary TB infects immunologically naive hosts — the organism lands in well-ventilated, high-airflow lower and middle lung zones, forming the Ghon focus (parenchymal granuloma + hilar lymph node = Ghon complex). Reactivation occurs later when immunity wanes, but by then the organism preferentially thrives in the upper lobes because higher oxygen tension favors M. tuberculosis growth. Mixing these up on a vignette means misidentifying which phase of disease the patient is in — primary is lower/middle zone, reactivation is upper lobe cavitary.
Common mistake
Wrong: PPD (tuberculin skin test) is equally reliable as IGRA in immunocompromised patients.
Right: IGRA (QuantiFERON-TB Gold) is preferred over PPD in immunocompromised patients because it is less affected by anergy and does not cross-react with BCG vaccination.
PPD measures the skin's delayed hypersensitivity response, which requires a functioning T-cell system — immunocompromised patients (HIV, transplant, chemotherapy) can have false-negative PPDs due to anergy, not because they lack TB. IGRA (QuantiFERON-TB Gold) measures interferon-gamma released by sensitized T cells in vitro, so it doesn't depend on an intact skin response and is less prone to anergy-related false negatives. Additionally, BCG vaccination causes false-positive PPDs but does not affect IGRA results, making IGRA the preferred test in BCG-vaccinated patients.
Common mistake
Wrong: Rifampin's primary toxicity is peripheral neuropathy.
Right: Rifampin's primary toxicities are hepatotoxicity and potent CYP450 induction (causing drug interactions); peripheral neuropathy is the main toxicity of isoniazid.
Peripheral neuropathy belongs to isoniazid, full stop — INH inhibits pyridoxine (B6) metabolism, and B6 is essential for myelin synthesis, so you get a sensorimotor neuropathy in deficient patients. Rifampin's signature toxicities are hepatotoxicity and potent CYP450 enzyme induction, which reduces the efficacy of many co-administered drugs (oral contraceptives, warfarin, HIV antiretrovirals, etc.). On Step 1, a vignette about a patient on multiple medications whose drug levels drop after starting TB therapy is pointing at rifampin's CYP induction, not neuropathy.
Common mistake
Wrong: Pyridoxine (B6) supplementation with isoniazid is optional and only for symptomatic patients.
Right: Pyridoxine is given prophylactically with isoniazid to all at-risk patients (malnourished, pregnant, alcoholic, diabetic, HIV+) because INH competitively inhibits B6 metabolism, causing peripheral neuropathy.
INH competitively inhibits the enzyme that activates pyridoxine (vitamin B6), so patients on INH gradually deplete functional B6 even if dietary intake is adequate — this causes peripheral neuropathy before symptoms become obvious. That's why pyridoxine is given prophylactically to at-risk groups (malnourished, pregnant, alcoholics, diabetics, HIV-positive patients) from day one of INH therapy, not after neuropathy develops. Waiting for symptoms to appear before starting B6 is the wrong model — by that point, nerve damage has already occurred.
Common mistake
Gap: Missing Pott disease as the named syndrome for vertebral TB with potential cord compression
Pott disease is TB osteomyelitis of the vertebral bodies (most commonly lower thoracic), which can cause vertebral collapse and a gibbus deformity with potential cord compression.
Pott disease is TB osteomyelitis of the vertebral bodies, most commonly the lower thoracic spine, caused by hematogenous seeding during primary or reactivation TB. The infection destroys the vertebral bodies and intervertebral discs, leading to vertebral collapse, anterior wedging, and a characteristic kyphotic hump called a gibbus deformity. The danger is that paravertebral abscess or bone collapse can compress the spinal cord, causing paraplegia — this named syndrome needs to come to mind immediately when a TB vignette mentions back pain, vertebral destruction, or neurological deficits.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Distinguish primary TB (Ghon focus in lower/middle lung zones, often asymptomatic) from reactivation TB (upper lobe cavitary disease, high O2 tension) from miliary TB (hematogenous dissemination, 'millet seed' pattern on CXR) — including which immune context favors each.
  2. Identify the named extrapulmonary TB syndromes: Pott disease (vertebral TB → gibbus deformity, cord compression), scrofula (cervical lymphadenopathy), lupus vulgaris (skin), and meningitis — and recognize them from vignette descriptions.
  3. Choose between PPD and IGRA given patient-specific factors: BCG vaccination status, immunocompromised state, reliability, and interpretation of results (including two-step testing and cutoff thresholds by risk group).
  4. Match each drug in the RIPE regimen to its specific toxicity: Rifampin (hepatotoxicity, orange secretions, CYP450 inducer), Isoniazid (peripheral neuropathy → B6 deficiency, hepatotoxicity, SLE-like), Pyrazinamide (hyperuricemia/gout, hepatotoxicity), Ethambutol (optic neuritis → red-green color blindness).

Can you avoid these mistakes?

A 35-year-old recent immigrant from a TB-endemic country has a positive PPD. He reports receiving BCG vaccination as a child. His chest X-ray is normal and he has no symptoms. Which diagnostic test should be ordered next, and why is PPD alone insufficient to guide management in this patient?
A chest X-ray from a 60-year-old immunosuppressed patient shows a cavitary lesion in the right upper lobe with surrounding consolidation. Is this more consistent with primary or reactivation TB? What pathophysiologic reason explains this lesion's location?
A patient starting RIPE therapy for active pulmonary TB asks why they're also being given a vitamin supplement. Which drug in the regimen requires this supplementation, what vitamin is it, and what will happen without it in a malnourished patient?
A 45-year-old with known pulmonary TB presents with progressive mid-back pain over 3 months. Imaging shows destruction of two adjacent thoracic vertebral bodies with a paravertebral soft tissue mass and anterior wedging. Name the syndrome, identify the organism's route to this site, and describe the most dangerous complication.

Related topics

Bacterial Staining and Structure Bacterial Culture Requirements Encapsulated Organisms Bacterial Exotoxins

See how your Anki deck covers this topic.

Upload your deck for a free audit →